A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of MK-0431 Monotherapy in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control
Latest Information Update: 06 May 2022
At a glance
- Drugs Sitagliptin (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 01 Feb 2014 Results published in the Drugs and Aging.
- 10 May 2010 Actual end date (Feb 2007) added as reported by ClinicalTrials.gov.
- 03 Oct 2006 Status change